ASGCT Gene Therapy Clinical Trial Highlights From Pfizer, Rocket Pharma, OSU, Ultragenyx, and More
At the meeting, companies and academic centers shared early and long-term follow-up data on investigational gene therapies for DMD, Danon disease, AADC, and other rare diseases.
Thermo Fisher Scientific, Pfizer Partner to Bring NGS-Based Cancer Tests to Underserved Markets
The collaboration will expand NGS-based tests for lung and breast cancers in more than 30 countries, where advanced genomic testing has been limited.
The drugmaker is hyping its recent acquisition announcement against an overall 29 percent revenue decline and 4 percent oncology sales dip during Q1 2023.
FDA Accepts Pfizer sNDAs for Braftovi, Mektovi in BRAF V600E-Mutant NSCLC
The sNDA submissions include data from the Phase II PHAROS trial, results from which researchers will present at an upcoming medical meeting.
Pfizer Acquires Seagen in $43B Deal
Pfizer will gain Seagen's anti-HER2 therapy Tukysa along with its pipeline of oncology drug candidates.